Clinical Trial Update: BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

BEACON is a Phase 1/2 study evaluating BEAM-101 for severe sickle cell disease; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• BEAM-101

Snippet

Sponsor: Beam Therapeutics Inc. | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING